SCHEMBL336000

SCHEMBL336000

CCN(CC)Cc1cc(C(C)NCCN)ccc1O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 1/20 0.51
ACHE P22303 1/20 0.50
POLB P06746 2/20 0.46
ALDH1A1 P00352 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MEN1 O00255 1/20 0.46
MAPT P10636 1/20 0.46
THRB P10828 1/20 0.46
APEX1 P27695 1/20 0.46
MAPK1 P28482 1/20 0.46
HTT P42858 1/20 0.46
RECQL P46063 1/20 0.46
CACNA1B Q00975 1/20 0.46
APBA1 Q02410 1/20 0.46
KMT2A Q03164 1/20 0.46
MCL1 Q07820 1/20 0.46
HKDC1 Q2TB90 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
JAK2 O60674 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL335409 0.84 PKM (0.45) ACHEALDH1A1CA2PKMALOX15
SCHEMBL10243850 0.80 POLB (0.43) PRKCIACHEPOLBALDH1A1TDP1
SCHEMBL336033 0.80 PRKCE (0.37) ALDH1A1TDP1KDM4EMEN1MAPT
SCHEMBL334300 0.74 CACNA1B (0.52) ACHEALDH1A1MAPK1HTTCACNA1B
SCHEMBL335431 0.73 NFKB1 (0.57) ACHEMAPK1GAABCHECYP3A4
SCHEMBL2485343 0.73 PRKCI (0.59) PRKCIACHEPOLBALDH1A1TDP1
SCHEMBL18575578 0.72 HTR1A (0.50) ALDH1A1MEN1MAPTHTTKMT2A
SCHEMBL335144 0.71 ESR1 (0.45) ALDH1A1TDP1KDM4EMEN1MAPT
SCHEMBL10243926 0.69 PKM (0.46) ACHEALDH1A1PKMALOX15BCHE
SCHEMBL111109 0.69 PRKCI (1.00) PRKCIACHEPOLBALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
EP-1985620-A1 10a-AZALIDE COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2008-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 PRKCI 3441/4885ACHE 1324/4885POLB 3348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.